Clinical Trial Search

Primary: Number of Participants Who Were Pain Free at 2 Hours Post-dose — 14; 28; 26; 36 participants — p=0.003

Primary: Number of Migraine/Migrainous Days Per 28 Day Period — 3.6; 4.9 days

Primary: Number of Participants With 2-hour Pain Free Active Study Drug — 35; 23; 21; 24 Participants — p=0.0038

Primary: Pharmacokinetics Outcome (1 of 6) — 1411.96; 0.00; 649.78; 1123.88 ng/mL

Primary: The Number of Subjects With a Numeric Rating Scale Score (NRS) of Zero at Two Hours. — 5; 12 participants — p=0.03

Primary: Pain-free Status at 2 Hours Post-treatment — 42; 20; 20; 68 Participants — p=.312

Primary: Number of Participants With the Indicated Drug-related Adverse Events — 93; 46; 170; 19 participants

Primary: Pain-relief — 5.6; 5.1; 2.25; 2.2 units on a scale*hr

Primary: Change in Mean Visual Analog Scale (VAS) Score — -2.3; -2.7 cm

Primary: Number of Pain Free Headaches at 2 and 24 Hours Post-Dose — 3218; 5236; 3048 Number of headaches

Primary: Pain Freedom at 2 Hours Post Dose in Participants Between 12 and 17 Years of Age — 87; 63; 197; 223 participants — p=0.025

Primary: Safety and Tolerability of Single Doses of Rizatriptan in Pediatric Migraineurs — 0; 0; 0; 3 Participants

Primary: Percentage of Participants Who Reported Pain Relief at 120 Minutes Post-Treatment — 38.6; 31.1 percentage of participants — p=0.345

Primary: Pain Relief at 2 Hours During the First Migraine Attack Period — 246; 30; 74; 52 participants

Primary: Assessment of Recruitment Rate — 1.1; 0.6 participants per month

Primary: Rate of Device Related Adverse Events — 0 Participants

Primary: Time to Maximum Concentration (Tmax) of Erenumab — 7.0; 7.0; 9.0; 7.0 days

Primary: Number of Participants With Adverse Events (AEs) Within 24 Hours Post Any Dose — 322 participants

Primary: The Percentage of Subjects in the Double-blind Period Who Are Pain Free at 2 Hours After Dosing as Reported by the Subject in the eDiary — 51.0; 30.8 Percentage of…

Primary: Change From Baseline in the Frequency of Headache Days — 23.2; 23.4; 25.3; -6.3 Headache days

Primary: Mean Change in Pain Intensity Scores Measured by the Numeric Analog Scale (NRS) — 2.3; 1.1 score on a scale — p=0.013

Primary: Headache Recurrence at 48 Hours — 1; 1 Participants

Primary: Mean Change From Baseline in the Number of Migraine Headache Days in the Last 28-day Period of the 12-week Treatment Phase — -4.2; -3.0 Migraine headache days

Primary: Adherence to Acute Migraine Management Strategies: Treat Early — 0; 2 Participants

Primary: Sustained Freedom From Migraine Pain Between 2-24 Hours Post-dose — 10; 41 Participants — p=<0.001

Primary: Change in MMD (Monthly Migraine Days) — -3.04; -2.14 migraine days per month

Primary: Pain-Relief at 2 Hours Post-treatment — 56; 65; 66 Participants

Primary: Number of Subjects With Pain Relief at 2 Hours From Time of First Dose — 136; 231 participants

Primary: Sustained Freedom From Migraine Pain Between 2-24 Hours Post-dose — 10; 36 Participants — p=<0.001

Primary: Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Lasmiditan — 362; 426 nanograms per milliliter (ng/mL)